Skip to main content
. Author manuscript; available in PMC: 2023 Sep 15.
Published in final edited form as: J Neuroimmunol. 2022 Jul 15;370:577931. doi: 10.1016/j.jneuroim.2022.577931

Table 1.

Demographic and clinical information on pediatric NMDARE patients (N = 36).

All patients
Age (mean, SD) 11.2 (5.2)
Female, N (%) 24 (67)
Race, N (%)
 American Indian/Alaska Native 1 (3)
 Black 21 (58)
 Mixed 1 (3)
 Unknown 5 (14)
 White 8 (22)
Ethnicity, N (%)
 Hispanic 8 (22)
 Non-Hispanic 27 (75)
 Unknown 1 (3)
ICU admission, N (%) 25 (69)
Intubated, N (%) 18 (50)
IV steroids, N (%)a 35 (100)
IVIG, N (%) 35 (97)
PLEX, N (%) 23 (64)
Second Line (Rituximab or cyclophosphamide), N (%) 26 (72)
Tumor present, N (%) 5 (14)
Prior ED visit or hospitalization before diagnosis, N (%) 28 (78)
Length of hospitalizationa Days, median (IQR) 22 (12–40)
MRI abnormal,a N (%) 17 (49)
EEG abnormal, N (%) 31 (86)
WBC Mean (SD) 9.1 (3.6)
NLR Median (IQR) 2.3 (1.3, 3.9)
LMR Mean (SD) 4.8 (2.3)
CSF WBC Median (IQR) 11.0 (3.0, 38.0)
Modified Rankin Scale at one year 2.2 (1.2)

SD: standard deviation, ICU: intensive care unit, IV: intravenous, IVIG: intravenous immunoglobulin, PLEX: plasmapheresis, ED: emergency department, LMR: lymphocyte to monocyte ratio; MRI: magnetic resonance imaging, EEG: electroencephalography, WBC: white blood cell, NLR: neutrophil to lymphocyte ratio, CSF: cerebrospinal fluid, IQR: interquartile range.

a

1 missing.